Cargando…

Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model

BACKGROUND: The evolution of drug-resistant parasites is a major hindrance to malaria control, and thus understanding the behaviour of drug-resistant mutants is of clinical relevance. The study aimed to investigate how resistance against lumefantrine (LU) and piperaquine (PQ), anti-malarials used as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gimode, Winnie R, Kiboi, Daniel M, Kimani, Francis T, Wamakima, Hannah N, Burugu, Marion W, Muregi, Francis W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336485/ https://www.ncbi.nlm.nih.gov/pubmed/25627576 http://dx.doi.org/10.1186/s12936-015-0550-5

Ejemplares similares

Plasmodium berghei ANKA: Selection of resistance to piperaquine and lumefantrine in a mouse model
por: Kiboi, D.M., et al.
Publicado: (2009)

Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment
por: Omondi, Protus, et al.
Publicado: (2019)

Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya
por: Gachie, Beatrice, et al.
Publicado: (2023)

Deciphering the targets of retroviral protease inhibitors in Plasmodium berghei
por: Onchieku, Noah Machuki, et al.
Publicado: (2018)

In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
por: Dormoi, Jérome, et al.
Publicado: (2014)

Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenafi, et al.
Publicado: (2022)

Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model
por: Odhiambo, Onyango C., et al.
Publicado: (2017)

Correction: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenaf, et al.
Publicado: (2023)

Antiplasmodial Activity Assay of 3-Chloro-4-(4-chlorophenoxy) Aniline Combinations with Artesunate or Chloroquine In Vitro and in a Mouse Model
por: Wekesa Sifuna, Martin, et al.
Publicado: (2019)

Electrocardiographic effect of artemisinin-piperaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine treatment in falciparum malaria patients
por: Wu, Wanting, et al.
Publicado: (2021)

Resistance of a Rodent Malaria Parasite to a Thymidylate Synthase Inhibitor Induces an Apoptotic Parasite Death and Imposes a Huge Cost of Fitness
por: Muregi, Francis W., et al.
Publicado: (2011)

Isolation of Mutants With Reduced Susceptibility to Piperaquine From a Mutator of the Rodent Malaria Parasite Plasmodium berghei
por: Ikeda, Mie, et al.
Publicado: (2021)

Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area
por: Song , Jianping, et al.
Publicado: (2011)

Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children
por: Nambozi, Michael, et al.
Publicado: (2011)

Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015
por: Plucinski, Mateusz M., et al.
Publicado: (2017)

Efficacy of artesunate–amodiaquine, dihydroartemisinin–piperaquine and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger
por: Grandesso, Francesco, et al.
Publicado: (2018)

A randomized trial of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
por: Dama, Souleymane, et al.
Publicado: (2018)

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda
por: Ebong, Chris, et al.
Publicado: (2021)

Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda
por: Ebong, Chris, et al.
Publicado: (2022)

Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation
por: Funck-Brentano, Christian, et al.
Publicado: (2019)

Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda
por: Taylor, Aimee R., et al.
Publicado: (2016)

Recurrence of Plasmodium malariae and P. falciparum Following Treatment of Uncomplicated Malaria in North Sumatera With Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine
por: Lubis, Inke Nadia D, et al.
Publicado: (2020)

Artemether–lumefantrine and dihydroartemisinin–piperaquine treatment outcomes among children infected with uncomplicated Plasmodium falciparum malaria in Mwanza, Tanzania
por: Marwa, Karol J., et al.
Publicado: (2021)

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects
por: Green, Justin A., et al.
Publicado: (2016)

Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
por: Hamaluba, Mainga, et al.
Publicado: (2021)

In vivo antiplasmodial activities of stem bark extracts of Avicennia marina in Plasmodium berghei-infected mice
por: Wilfred, Gitau, et al.
Publicado: (2023)

Efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated malaria in Papua New Guinea
por: Tavul, Livingstone, et al.
Publicado: (2018)

Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial
por: Kamya, Moses R, et al.
Publicado: (2007)

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
por: Staehli Hodel, Eva Maria, et al.
Publicado: (2013)

Antimalarial Efficacy of Aqueous Extract of Strychnos ligustrina and Its Combination with Dihydroartemisinin and Piperaquine Phosphate (DHP) against Plasmodium berghei Infection
por: Cahyaningsih, Umi, et al.
Publicado: (2022)

Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania
por: Mori, Amani T, et al.
Publicado: (2014)

Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa
por: Yavo, William, et al.
Publicado: (2011)

Efficacy and safety of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017
por: Davlantes, Elizabeth, et al.
Publicado: (2018)

Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance
por: Small-Saunders, Jennifer L., et al.
Publicado: (2022)

Plasmodium falciparum phenotypic and genotypic resistance profile during the emergence of Piperaquine resistance in Northeastern Thailand
por: Boonyalai, Nonlawat, et al.
Publicado: (2021)

In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene
por: Pascual, Aurélie, et al.
Publicado: (2013)

Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials
por: Wicht, Kathryn J, et al.
Publicado: (2022)

Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?
por: Foguim Tsombeng, Francis, et al.
Publicado: (2019)

Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018
por: Gansané, Adama, et al.
Publicado: (2021)

Dihydroartemisinin-Piperaquine vs. Artemether-Lumefantrine for First-Line Treatment of Uncomplicated Malaria in African Children: A Cost-Effectiveness Analysis
por: Pfeil, Johannes, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_75urs0hvtaql4e7hunrg16u5sr